De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Icure Pharmaceutical Incorporation Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	geen gegevens

Recente managementupdates

Geen updates

Recent updates

Icure Pharmaceutical Incorporation (KOSDAQ:175250) May Have Run Too Fast Too Soon With Recent 26% Price Plummet

Sep 04

Is Icure Pharmaceutical Incorporation (KOSDAQ:175250) A Risky Investment?

Aug 28

What Icure Pharmaceutical Incorporation's (KOSDAQ:175250) 27% Share Price Gain Is Not Telling You

Jul 21

Icure Pharmaceutical Incorporation (KOSDAQ:175250) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

May 31

Is Icure Pharmaceutical Incorporation (KOSDAQ:175250) Using Debt In A Risky Way?

May 27

Some Shareholders Feeling Restless Over Icure Pharmaceutical Incorporation's (KOSDAQ:175250) P/S Ratio

Mar 07

We Think Icure Pharmaceutical Incorporation (KOSDAQ:175250) Has A Fair Chunk Of Debt

Dec 25

CEO

Icure Pharmaceutical Incorporation heeft geen CEO, of we hebben geen gegevens over hen.

Icure Pharmaceutical Incorporation Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Recent updates

Icure Pharmaceutical Incorporation (KOSDAQ:175250) May Have Run Too Fast Too Soon With Recent 26% Price Plummet

Is Icure Pharmaceutical Incorporation (KOSDAQ:175250) A Risky Investment?

What Icure Pharmaceutical Incorporation's (KOSDAQ:175250) 27% Share Price Gain Is Not Telling You

Icure Pharmaceutical Incorporation (KOSDAQ:175250) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

New minor risk - Share price stability

Is Icure Pharmaceutical Incorporation (KOSDAQ:175250) Using Debt In A Risky Way?

Full year 2023 earnings released: ₩837 loss per share (vs ₩1,793 loss in FY 2022)

Some Shareholders Feeling Restless Over Icure Pharmaceutical Incorporation's (KOSDAQ:175250) P/S Ratio

New major risk - Share price stability

New major risk - Financial position

New minor risk - Share price stability

Icure Pharmaceutical Incorporation announced that it has received KRW 5 billion in funding

Icure Pharmaceutical Incorporation has completed a Follow-on Equity Offering in the amount of KRW 34.32972 billion.

New 90-day low: ₩56,500

Icure Pharmaceutical Incorporation announced that it has received KRW 50 billion in funding

We Think Icure Pharmaceutical Incorporation (KOSDAQ:175250) Has A Fair Chunk Of Debt

New 90-day high: ₩75,300

New 90-day high: ₩62,500

New 90-day high: ₩54,700

Prostemics Co., Ltd. (KOSDAQ:A203690) agreed to acquire OTKCNT Co., Ltd. from Icure Pharmaceutical Incorporation (KOSDAQ:A175250) and Gang, Seok-Ho for KRW 17 billion.

CEO